Literature DB >> 32337159

Fatal HBoV-1 infection in adult female cystic fibrosis patient.

Doris Dieninghoff1, Christian Karagiannidis1, Stephan Straßmann1, Monika Pieper2, Sarah Dammaschek2, Joseph Zabner3, Aloysius Klingelhutz3, Wolfram Windisch1, Michael Brockmann2, Oliver Schildgen2, Verena Schildgen2.   

Abstract

A clinical case of fatal HBoV infection in an adult cystic-fibrosis patient awaiting lung transplantation is reported. The case is important as the genetic background of the underlying disease is congruent with the background of the sole permissive permanent cell culture CuFi-8 which originates also from a CF patient donor.
© 2016 The Authors.

Entities:  

Year:  2016        PMID: 32337159      PMCID: PMC7172079          DOI: 10.1016/j.ehpc.2016.07.001

Source DB:  PubMed          Journal:  Hum Pathol (N Y)        ISSN: 2214-3300


The human bocavirus (HBoV) is a parvovirus that is associated with acute and chronic infections of the upper and lower respiratory tract, persists in some tissues and solid cancers and putatively may play an aetiologic role in the development of idiopathic lung fibrosis [1], [2], [3], [4], [5], [6], [7], [8]. The viral infection can switch between long term periods of viral shedding and silent phases of latency [9]. To date, no animal model exists, thus studies on the pathology of HBoV infections are limited to clinical studies, case descriptions, and air-liquid interface cell culture models that have been shown to mimic some important steps of the infection cycle [1], [7], [10], [11], [12]. The latter infections models are based on either primary cells that can be differentiated into organ like tissues from primary cells [1], [7], [11], [12], [13] or CuFi-8 cells [1], [10], [13]. CuFi-8 is a cell line derived from a 24 year old female patient suffering from cystic fibrosis; the cell line carries the mutation pattern ∆ F508/∆F508 (the most common CF associated mutation) and is an immortalized human epithelial airway cell line from the bronchus of the patient; the immortalization was performed with Weinberg hTERT and HPV-16 E6/E7 [10], [14]. This information might be relevant for a current clinical case that was treated in our hospital in Cologne. The patient was a 24 year old non-smoking Caucasian cystic fibrosis patient. She was regularly treated in our cystic fibrosis outclinics and was deemed to be eligible for lung transplantation shortly before the fatal clinical episode started. In advance to the lung transplantation, a microbiological check-up revealed colonization of the lung with low titres of Aspergillus and a multi-resistant Pseudomonas aeruginosa strain, combined with allergic asthma, pancreatic insufficiency, and malnutrition (BMI 14–15 kg/m2). In order to overcome the malnutrition, percutaneous endoscopic gastrostomy (PEG) was required and initiated in our hospital. The patient started to recover well, episodically required non-invasive ventilation (NIV), but was in a condition stable enough to continue NIV at home. The night before the patient should have left the hospital she developed an ARDS unexpectedly and was shifted to our intensive care unit. During intensive care treatment, despite expected obstipation, the patient developed massive diarrhea. In order to identify a pathogen causative for the ARDS, a BAL was performed and analysed for respiratory bacteria and viruses. An all-embracing molecular and microbiological diagnostic algorithm was performed as described earlier [15], [16], [17], including molecular screening for human herpesviruses 1–8, Parechoviruses, Rhino- and Enteroviruses, Adenoviruses, Influenza A and B virus including H1N1, Human metapneumovirus, respiratory syncytial virus A and B, Coronaviruses 229E, OC43, HKU-1, NL63, parainfluenzaviruses 1–4, mumps and measles, and human bocavirus, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, and Bordetella pertussis, but revealed human bocavirus as the sole pathogen detectable in the BAL during the fatal clinical flare of the ARDS. Detailed protocols for the diagnostic procedures were published previously [1], [9], [16], [17], [18]. Moreover, any attempts to culture further respiratory pathogens including Mycobacterium tuberculosis and atypical mycobacteria revealed negative results. Although the clinical course could have been triggered by the Pseudomonas aeruginosa or Aspergillus colonization and no Pseudomonas cepacia infection was differentially excluded, the most likely explanation for the fatal outcome remains the sole infection with human bocavirus. In this context it is important to note, that the patient was homozygous for the cystic fibrosis genotype ∆ F508/∆F508, and as the donor of the CuFi-8 cell line, at the time point of death was 24 years of age. It is important to mention, that the BAL was characterized by serious bleeding, which may have contributed to the clinical outcome. This bleeding is another parallel to the CuFi-8 cells: The cells are permissive for HBoV if they are seeded to filter membranes and differentiated to pseudostratified air-liquid interface cultures; thereby, they fall dry and develop a mucus layer on top, while receiving nutrition from the basal medium. If those air-liquid interface cultures are infected with HBoV they develop a serious cytopathic effect and may become “leaky”, i.e. the basal cell culture medium passes the membrane, which can be compared to the clinical bleeding. The fact that age, sex, and genetic phenotype for the patient and the permissive CuFi-8 cell culture were equal solicits the cautious conclusion that the patient was highly permissive for the HBoV infection and died because of the serious damages the virus initiated. This hypothesis is further supported by the fact that the patient suffered from diarrhea, although cystic fibrosis in concert with pancreatic insufficiency is generally accompanied by obstipation. In this context it is important to mention that HBoV-1 is not generally associated with diarrhea but is observed in HBoV-2 and 3 infections [19], [20], [21], [22]; however, HBoV-1 can be shed via the gastrointestinal route after swallowing and was repeatedly found in colorectal malignancies [23], [24]. Unfortunately, due to the fact that the clinical course progresses so rapidly, and that the clinical colleagues were not aware of the parallels between the genetic background of the CuFi-8 cells and the patient, no further clinical specimen were collected for scientific purposes, thus no further laboratory investigations could be performed, although this would not have changed the clinical decision making. This is a considerable limitation of our report, which in our view still contains important hints regarding the pathogenesis of HBoV. Taking into account the fact that it remains formally difficult to attribute clinical causalities to human bocavirus as previously discussed by Martin [25] and Byington [26], a permissive animal model for studying HBoV pathology would be a great advantage. However, although exclusively investigating a clinical cohort, Byington [26] and coworkers have unintendedly confirmed the assumption that HBoV is indeed a true pathogen rather than a blind and silent passenger [27], which was further confirmed by our recent translation study in which we have shown that HBoV-1 induces a profibrotic and procancerogenic cytokines expression in vivo and in vitro [1]. We also have to critically discuss the putative link between the CF genotype of the patient and the cell culture and its relation to the severe outcome of the HBoV infection. So far it remains a matter of speculation if there is a causality between these co-incidences or if the clinical case was just a rare event that was congruent to our observations in cell culture. However, it remains possible that such a causative link exists and therefore this clinical case presentation is intended to trigger further research in this direction. As a consequence, more detailed clinical studies that focus on the high risk group of cystic fibrosis patients suffering from HBoV infections are required, and it needs to be tested in vitro if cystic fibrosis specific factors contribute to a more severe clinical course of the HBoV infection of those patients.

Ethical approval

All procedures described in this case report were performed with approval from the Ethic Committee of the University of Witten (vote 73/2012).

Conflict of interest declaration

The authors declare that no conflict of interest apply according to the ICMJE definitions.

Funding

No funding was available for this report.
  24 in total

1.  Respiratory Infections With Human Bocavirus.

Authors:  Oliver Schildgen; Verena Schildgen
Journal:  Clin Infect Dis       Date:  2015-09-03       Impact factor: 9.079

Review 2.  New molecular approaches in the diagnosis of acute diarrhea: advantages for clinicians and researchers.

Authors:  Alfredo Guarino; Antonietta Giannattasio
Journal:  Curr Opin Gastroenterol       Date:  2011-01       Impact factor: 3.287

3.  Development of cystic fibrosis and noncystic fibrosis airway cell lines.

Authors:  Joseph Zabner; Phil Karp; Michael Seiler; Stacia L Phillips; Calista J Mitchell; Mimi Saavedra; Michael Welsh; Aloysius J Klingelhutz
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-01-10       Impact factor: 5.464

4.  In vitro modeling of human bocavirus 1 infection of polarized primary human airway epithelia.

Authors:  Xuefeng Deng; Ziying Yan; Yong Luo; Jian Xu; Fang Cheng; Yi Li; John F Engelhardt; Jianming Qiu
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

5.  Human bocavirus in an immunocompromised child presenting with severe diarrhea.

Authors:  Jutte J C de Vries; Robbert G M Bredius; Patrick F van Rheenen; Frans J W Smiers; Elisabeth H Schölvinck; Ann C T M Vossen; Eric C J Claas; Hubert G M Niesters
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

6.  Detection of HBoV DNA in idiopathic lung fibrosis, Cologne, Germany.

Authors:  Wolfram Windisch; Verena Schildgen; Monika Malecki; Johannes Lenz; Michael Brockmann; Christian Karagiannidis; Oliver Schildgen
Journal:  J Clin Virol       Date:  2013-06-24       Impact factor: 3.168

7.  Acute human bocavirus infection in MDS patient, Cologne, Germany.

Authors:  Michael Krakau; Michael Brockmann; Bärbel Titius; Christina Limmroth; Soumaya Khalfaoui; Verena Schildgen; Arno Dormann; Oliver Schildgen
Journal:  J Clin Virol       Date:  2015-06-03       Impact factor: 3.168

8.  Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia.

Authors:  Qinfeng Huang; Xuefeng Deng; Ziying Yan; Fang Cheng; Yong Luo; Weiran Shen; Diana C M Lei-Butters; Aaron Yun Chen; Yi Li; Liang Tang; Maria Söderlund-Venermo; John F Engelhardt; Jianming Qiu
Journal:  PLoS Pathog       Date:  2012-08-30       Impact factor: 6.823

9.  Lung Infection by Human Bocavirus Induces the Release of Profibrotic Mediator Cytokines In Vivo and In Vitro.

Authors:  Soumaya Khalfaoui; Vivien Eichhorn; Christian Karagiannidis; Inga Bayh; Michael Brockmann; Monika Pieper; Wolfram Windisch; Oliver Schildgen; Verena Schildgen
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

10.  Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.

Authors:  Ashleigh Manning; Samantha J Willey; Jeanne E Bell; Peter Simmonds
Journal:  J Infect Dis       Date:  2007-03-21       Impact factor: 5.226

View more
  2 in total

1.  Severe Human Bocavirus-Associated Pneumonia in Adults at a Referral Hospital, Seoul, South Korea.

Authors:  Sang-Ho Choi; Jin Won Huh; Sang-Bum Hong; Jiwon Jung; Min Jae Kim; Yong Pil Chong; Sung-Han Kim; Heungsup Sung; Eun Jin Chae; Kyung-Hyun Do; Sang-Oh Lee; Chae-Man Lim; Yang Soo Kim; Jun Hee Woo; Younsuck Koh
Journal:  Emerg Infect Dis       Date:  2021-01       Impact factor: 6.883

2.  High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery.

Authors:  Matthias Obenaus; Oliver Schildgen; Dirk Schürmann; Ann-Christin von Brünneck; Martin Janz; Ulrich Keller; Bernhard Gebauer; Johannes Schilling; Stefan Schwartz; Benedikt Weissbrich; Thomas Schneider; Jörg Hofmann; Stephan Mathas
Journal:  ERJ Open Res       Date:  2021-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.